Printer Friendly

Studies Support Usefulness of Nymox's AD7C-TM Test in Alzheimer's Disease.

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 11, 1998--The usefulness of Nymox Pharmaceutical Corporation's (NASDAQ National Market: NYMXF; Montreal Exchange: NMX) AD7C(TM) test as an aid to the diagnosis of Alzheimer's Disease ("AD") was reinforced by two research papers given at this week's annual Society for Neuroscience meeting in Los Angeles, California.

Dr. Hossein Ghanbari, Senior Vice President of Nymox, presented data from several independent studies which have established that AD7C(TM) measured in urine or in spinal fluid closely mirrors the disease process in the brain. Dr. Ghanbari presented results from double blind coded clinical trials using samples from independent physicians at multiple centers in the U.S. The results indicated that urinary AD7C(TM) correlates over 90% with spinal AD7C(TM) and that the concordance is over 80%. Both urinary and spinal AD7C(TM) measurements are used clinically to aid the physician in the diagnosis of AD. Dr. Ghanbari emphasized that urinary AD7C(TM) is a painless peripheral test that has great potential for monitoring drug trials and therapies, as well as for assisting diagnosis.

In a second paper, another independent study which looked at AD7C(TM) in AD was reported by Dr. Philipp Kahle of Stanford University (478.10; Microtubule-Associated Protein Tau and AD7C-Neural Thread Protein are Elevated in Cerebrospinal Fluid of Alzheimer's Disease Patients: Influence of Genetic Risk Factors. P.J. Kahle, G. Murphy, J.A. Yesavage, J.R. Tinklenberg and E.M. Shooter). The Stanford group found that AD7C(TM) has a sensitivity of 85% and a specificity of 90%. These values are similar to other previous independent studies of AD7C(TM) which have confirmed the accuracy of the test.

"These important studies further verify the accuracy and usefulness of AD7C(TM)," said Dr. Michael Munzar, Medical Director of Nymox. "The latest reported results prove beyond any statistical question that AD7C(TM) performance is consistent, reliable and above all of major usefulness. The urinary test is painless and practical and physicians are increasingly finding it helpful in their practice."

Nymox's AD7C(TM) urinary test for AD is newly available to physicians exclusively from Nymox's Reference Laboratory in Rockville, Maryland. For people with suspicious symptoms but who do not actually have AD, AD7C(TM) testing helps the physician rule out AD and reassures the patient. It also helps the physician find other causes of symptoms which are often successfully treatable such as depression, metabolic disorders and other conditions. AD7C(TM) testing also forms a biochemical numerical basis for treatment which helps doctors and researchers to evaluate the progress of the disease and the value of new treatments in an objective fashion. AD7C(TM) helps the physician be more confident in the diagnosis of AD, particularly in early cases. All aspects of medical care and family arrangements can be planned more thoroughly and more efficiently. The early diagnosis of AD on clinical grounds alone is imperfect and takes an average of about 3 years from the time of initial symptoms according to independent published studies. This is a long time of inestimable anxiety and anguish for the millions of patients and their families. AD7C(TM) has a potential to streamline and shorten the diagnostic work-up for AD and therefore produce significant savings for health care payers.

This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities.
COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 11, 1998
Words:617
Previous Article:Schwab Institutional and CMS Join in Bringing Internet Research Tool to Investment Professionals.
Next Article:Federated Diluted 3Q Earnings Total 50 Cents a Share.


Related Articles
Nymox Reports Favorable Results in 500 Patient Study of Test to Rule out Alzheimer's Disease.
Promising Results of Initial Clinical Studies for Nymox's New Urinary Test for Alzheimer's Disease.
Nymox to Begin Trading on NASDAQ on November 25, 1997.
Nymox Announces New Independent Study Results That Confirm and Extend the Accuracy, Specificity and Utility of AD7C Alzheimer Testing.
Nymox's Alzheimer Test Shown to Have Expanded Clinical Usefulness.
Nymox Corporation and Specialty Laboratories Agree to Co-Market AD7C -tm- Alzheimer's Test in the United States.
Nymox Corporation Announces Year-end Results.
New Publication of Peer-Reviewed Study in Neurology Independently Verifies Nymox AD7C Test.
First Urinary Alzheimer Diagnostic Aid by Nymox Proven to Be Accurate by New Peer Reviewed Publication.
Nymox Pharmaceuticals Corrects and Replaces Previous News Release, BW0151, NYMOX-PHARMACEUTICAL, Issued Earlier Tuesday.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters